Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TAR-210 versus intravesical chemotherapy in FGFR-altered intermediate-risk non-muscle invasive bladder cancer
2023-507684-19-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of erdafitinib, gemcitabine and mitomycin c in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival. Planned start Jul 2024; status: authorised.
02
Drugs
erdafitinibgemcitabinemitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2023-507684-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507684-19-00.